Orexo – Interim Report Q3 2018

UPPSALA, Sweden, Oct. 25, 2018 /PRNewswire/ — The win in the patent litigation strengthen Orexo’s long term business opportunities Q3 2018 highlights Orexo wins appeal against Actavis on Zubsolv patent in the US, expiring in 2032 Total net revenues of SEK 216.6 million (166.2), up 30.3…

Source: https://www.prnewswire.com:443/news-releases/orexo—interim-report-q3-2018-300737664.html